Allergan closes the book on Fetzima generics suit

Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima (Levomilnacipran).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie to acquire Allergan for $63bn

25 June 2019 US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.

Big Pharma

AbbVie’s pending Allergan takeover moves closer after drug divestments

28 January 2020 Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.

More on this story

Americas

AbbVie to acquire Allergan for $63bn

25 June 2019 US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.

Big Pharma

AbbVie’s pending Allergan takeover moves closer after drug divestments

More on this story

Americas

AbbVie to acquire Allergan for $63bn

25 June 2019 US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.

Big Pharma

AbbVie’s pending Allergan takeover moves closer after drug divestments